Our Mission: Highlighting Innovations by showcasing breakthroughs in cancer research, including diagnostic tools, therapies, and preventive measures.

NORDOT

Mersana stock falls after cancer drug data (MRSN:NASDAQ) | Seeking Alpha

Posted on

As of February 2025, Nordot Inc. has announced the termination of its curation service, which allowed users to utilize article headlines, effective March 31, 2025. This service enabled curators to access article titles, a lead image, and the initial 50 characters of the content for aggregation purposes. Post-termination, any redirection to article pages will no longer qualify for revenue sharing, and the provision of headlines for curators will cease. Users are advised to remove any curated content from their platforms by the specified date to comply with this change.

Despite the discontinuation of the curation service, Nordot will continue to offer its Content Holder Service. This service focuses on content distribution and syndication, assisting media outlets in disseminating their articles to external platforms. Nordot remains committed to providing infrastructure that enables media entities to share and distribute content efficiently, aiming to transform the media market sustainably. Click for More Details

error: Content is protected !!